Produced by NHS Rotherham Medicines Management Team Tel (01709) 302631 if further information required.

Rotherham Community Pharmacy Newsletter Easter 2012



NHS Rotherham

Controlled Drugs Accountable Officer

Stuart Lakin – Head of Medicines Management is now the Accountable Officer for Controlled Drugs for NHS Rotherham. All CD incidents need reporting via a CD incident Alert Form (IAF) by e-mail: **IAFs@rotherham.nhs.uk** or fax. 01709 302041

If the incident involves a prescription please keep a copy of the prescription with your copy of the IAF in case further investigation is required.

Class 4 Drug Alert: Epistatus, Midazolam 10mg in 1ml Buccal Liquid x 5ml (M11) - EL(12)A/08

Special Products Ltd carried out several modifications to this unlicensed product in December 2011. Information about the changes appears not to have been adequately passed on to users of the product and has the potential to result in product overdose.
Additional information can be found via:
http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&ssDocName=CON143794

Guidance for Hospital and Community Pharmacy Staff to Support Patient Discharge from Hospital

New guidance has been published to support the effective use of the new medicine service (NMS) and nationally targeted Medicine Use Review (MUR) service when patients are discharged from hospital

Additional information can be found via:
http://www.npc.nhs.uk/rapidreview/?p=4916

Let's Get Moving Resources

The Department of Health has published updated Let's Get Moving resources. These have been revised to bring them into line with current practice and the latest guidelines for physical activity. The revised resources are, a partners booklet that summarises the Let's Get Moving intervention and explains how to get involved, and a revised commissioning guidance that presents a systematic approach to identifying and supporting adults who are not meeting the exercise recommendations.

Additional information can be found via:
http://www.dh.gov.uk/health/2012/03/lets-get-moving/

Enhanced Services - Signposting

Please can we remind pharmacies that if you are unable to provide an Enhanced Service on that particular day to signpost patients to another pharmacy or Healthcare Provider who provide that service.

Substance Misuse Clients – Pharmacy Service User Treatment Agreement

Reminder to pharmacists of the above agreement between the service users, key worker and pharmacist which outlines the general operation and behavioral aspects of the service provided. The details must be discussed with the client and signed and kept with the current prescription as per the Service Level Agreement. Pharmacists are reminded that:

- Clients should be treated with dignity and respect
- Clients should be seen promptly to save them waiting in a queue
- They offer a user-friendly, non-judgmental, client-centred and confidential service

Any queries please contact Debbie Stovin on 01709 423503

IMPORTANT NOTICE 'NUTRITION AND DIETETICS REGARDING 'COMPLAN'

Just a little reminder to confirm that:
Dieticians will prescribe nutritional supplements for patients if they met the ACBC prescribing criteria set out by the GP Commissioners. If a patient does not fit these criteria for prescribing the Dietician may suggest to the patient they can buy Complan to help supplement their diets.
The pharmacist may feel that the patient may require nutritional supplements, but if that patient is seen by a Dietician, the Dietician will have assessed the patient for appropriate prescribing.

Unlicensed imported vitamin D (colecalciferol) capsules: potential peanut oil and soya oil allergens- *Drug Safety Update March 2012, vol 5 issue 8: S2.*

Vigantoletten and Dekristol vitamin D (colecalciferol) capsules are unlicensed medicines in the UK. However, they are legitimately imported and supplied in their original German language livery for the special needs of individual patients only on prescription under the direct responsibility of the prescriber. The German labelling of these products states that Vigantoletten capsules contain soya oil, and that Dekristol capsules contain arachis (peanut) oil. This is unlikely to be evident to non-German speakers. Healthcare professionals should be aware that these capsules contain potential allergens.
Furthermore, imported unlicensed vitamin D Osto D2 capsules from Canada and Drisdol capsules from the USA may pose a similar allergen risk. Although labelled in English, the products may not explicitly state that they contain soya oil.

Advice for healthcare professionals:

- **Allergy to soya oil or arachis oil may lead to severe allergic reactions, including anaphylaxis**
- **These products are contraindicated in patients with relevant allergies. Doctors and pharmacists should enquire whether patients have any relevant allergies before supplying these medicines**
- **Importers are advised that prescribers must be made aware of this contraindication**

Further information:
Drug safety information for Vigantoletten capsules
Drug safety information for Dekristol capsules
Unlicensed or off-label use of medicines: prescribersâ€™ responsibilities

Accredited guidance on combined hormonal and emergency contraception

NHS Evidence accredited provider

The Faculty of Sexual & Reproductive Healthcare (FSRH) has recently published clinical guidance on emergency contraception[1] and combined hormonal contraception[2]. The process used by the Clinical Effectiveness Unit of the FSRH to produce clinical guidance has been accredited by NHS Evidence.

Action
Healthcare professionals providing contraception or contraceptive advice should familiarise themselves with this clinical guidance. A summary of key recommendations is given at the start of each guidance document.

What are the main changes to previous guidance?
For combined hormonal contraception, the main changes from the previous guidance are the inclusion of:

- All combined hormonal methods (oral contraceptive pills, transdermal patch and vaginal ring)
- New advice in relation to combined hormonal contraception and antibiotics that do not induce enzymes (see MeReC Rapid Review No. 2586)
- New missed-pill advice (see also the MHRA Public Assessment Report on combined oral contraceptives, which discusses the rationale for changes to the product information for all combined oral contraceptive pills on when to start taking the pill and actions to take if a pill has been missed)
- Advice in relation to incorrect use of the contraceptive patch and ring
- Updated UK Medical Eligibility Criteria for Contraceptive Use.

The most significant change from previous guidance on emergency contraception is the inclusion of ulipristal acetate.

This guidance was signposted in MeReC Rapid Review No. 4786. Further information on contraception can be found on NHS Evidence and in the contraception e-learning section of the NPC website. For more information on the NHS Evidence Accreditation Scheme see the frequently asked questions on the NHS Evidence website.
References

1. FRSH. Clinical Effectiveness Unit clinical guidance. Emergency contraception. August 2011 (updated January 2012)
2. FRSH. Clinical Effectiveness Unit clinical guidance. Combined hormonal contraception. October 2011